| Q40635141 | A Phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium |
| Q33621281 | A phase II study of docetaxel and oxaliplatin for second-line treatment of urothelial carcinoma |
| Q33504597 | A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer |
| Q46910255 | A phase II study of mitomycin, fluorouracil, folinic acid, and irinotecan (MFI) for the treatment of transitional cell carcinoma of the bladder |
| Q36614243 | A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen |
| Q36115630 | A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced B |
| Q46033801 | A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. |
| Q33978824 | Advanced bladder and urothelial cancers |
| Q37791751 | Advanced bladder cancer: new agents and new approaches. A review. |
| Q37217466 | Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting |
| Q37812062 | Bladder Cancer: Current Management and Opportunities for a Personalized Approach |
| Q28082782 | Bladder cancer in the elderly patient: challenges and solutions |
| Q35615210 | Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder |
| Q33340282 | Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. |
| Q40714083 | Clinical significance of a second-line chemotherapy regimen with paclitaxel, ifosfamide and nedaplatin for metastatic urothelial carcinoma after failure of cisplatin-based chemotherapy |
| Q33340371 | Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group |
| Q33431220 | Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis |
| Q60918065 | Contemporary best practice in the management of urothelial carcinomas of the renal pelvis and ureter |
| Q35180823 | Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature. |
| Q37284023 | Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma |
| Q37789085 | Current chemotherapeutic options for the treatment of advanced bladder cancer: A review |
| Q37888549 | Current chemotherapeutic strategies against bladder cancer |
| Q35128721 | Current therapeutic strategies for invasive and metastatic bladder cancer. |
| Q38624895 | Docetaxel for the treatment of bladder cancer |
| Q52592611 | Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma. |
| Q40708483 | Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer |
| Q37163829 | Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium |
| Q34541463 | First- and second-line therapy for metastatic urothelial carcinoma of the bladder |
| Q35609563 | Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. |
| Q77952069 | Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer |
| Q44673128 | Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy |
| Q33978846 | Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer |
| Q40105858 | Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease |
| Q38777610 | Improving Systemic Chemotherapy for Bladder Cancer |
| Q26744758 | Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer |
| Q37523855 | Management of bladder cancer: current and emerging strategies |
| Q38798645 | Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU). |
| Q33377834 | Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy |
| Q44373064 | Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study. |
| Q33619249 | Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment |
| Q46174958 | Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study |
| Q34107997 | New approaches to treatment of metastatic bladder cancer |
| Q35192424 | New drugs and new approaches in metastatic bladder cancer |
| Q38233326 | Optimal treatment for metastatic bladder cancer |
| Q35097998 | Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group |
| Q33403679 | Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy |
| Q40446162 | Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group |
| Q37415341 | Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group |
| Q33426694 | Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma |
| Q53401747 | Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum. |
| Q37389950 | Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium |
| Q53658820 | Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. |
| Q40558439 | Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group |
| Q53584625 | Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. |
| Q33333726 | Phase II trial of pyrazoloacridine as second-line therapy for patients with unresectable or metastatic transitional cell carcinoma |
| Q35823355 | Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP). |
| Q35097970 | Progress in the chemotherapy of metastatic cancer of the urinary tract |
| Q33968726 | Progress in the management of metastatic bladder cancer |
| Q27010323 | Role of systemic chemotherapy in urothelial urinary bladder cancer |
| Q60921935 | SPAG9 regulates HEF1 expression and drives EMT in bladder transitional cell carcinoma via rac1 signaling pathway |
| Q34438928 | Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. |
| Q38612831 | Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. |
| Q37764163 | Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium |
| Q38155201 | Second-line systemic therapy for metastatic urothelial carcinoma of the bladder |
| Q37702430 | Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer |
| Q39974732 | Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model |
| Q34567910 | Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. |
| Q34657961 | Surgery and adjunctive chemotherapy for invasive bladder cancer |
| Q37466359 | Systemic therapy of advanced urothelial cancer |
| Q47102176 | The combination of paclitaxel and carboplatin as second-line chemotherapy can be a preferred regimen for patients with urothelial carcinoma after the failure of gemcitabine and cisplatin chemotherapy |
| Q60049823 | The continuing role of chemotherapy in the management of advanced urothelial cancer |
| Q35193683 | The systemic treatment of advanced and metastatic bladder cancer. |
| Q77665238 | Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial |
| Q73965178 | Transitional cell carcinoma of the bladder: new approaches to the treatment of advanced disease |
| Q33358122 | Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). |
| Q58694390 | Update on chemotherapy in the treatment of urothelial carcinoma |
| Q49192905 | Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease |
| Q42183149 | Vinflunine in the treatment of bladder cancer |
| Q43654255 | Weekly regimen of epirubicin and paclitaxel as second-line chemotherapy in patients with metastatic transitional cell carcinoma of urothelial tract: results of a phase II study |
| Q78898958 | [Advanced bladder cancer: new therapeutic strategies] |
| Q77734750 | [Chemotherapy for urothelial infiltrating tumors] |
| Q73146463 | [Neoplastic pathology of the urothelium] |